Type 2 Diabetes

Type 2 diabetes, formerly called adult-onset or noninsulindependent diabetes, is the most common form of diabetes. People can develop type 2 diabetes at any age, even during childhood. This form of diabetes usually begins with insulin resistance, a condition in which fat, muscle, and liver cells do not use insulin properly. At first, the pancreas keeps up with the added demand by producing more insulin. In time, however, it loses the ability to secrete enough insulin in response to meals. People who are overweight and inactive are more likely to develop type 2 diabetes. Treatment includes taking diabetes medicines, making wise food choices, exercising regularly, controlling blood pressure and cholesterol, and taking aspirin daily—for some.

What is Type 2 Diabetes?

Type 2 diabetes is a common metabolic condition that develops when the body fails to produce enough insulin or when insulin fails to work properly, which is referred to as insulin resistance. Insulin is the hormone that stimulates cells to uptake glucose from the blood to use for energy.

Does the Keto Diet Increase the Risk of Diabetes?

Insulin Medication

Fibromyalgia and Diabetes

Type 2 Diabetes Symptoms

Vitamin D and Type 2 Diabetes

Insulin Resistance Diagnosis

Living With Type 2 Diabetes

Insulin Resistance Symptoms

Insulin Resistance Pathophysiology

Insulin Resistance and Parkinson's Disease

Is a Plant-Based Diet Good for Type 2 Diabetes?

See more featured articles »

Type 2 Diabetes Screening and Prevention

Type 2 Diabetes Treatment

Type 2 Diabetes Diagnosis

Causes of Insulin Resistance

Insulin Resistance Treatment

What is Insulin Resistance?

Are Low Carbohydrate Diets Good for Type 2 Diabetes?

Diabetes Mellitus Type 2 Pathophysiology

Diabetes in Men versus Women

The Risks of Prediabetes

What is Diabetes?

Latest Type 2 Diabetes News and Research

Cholesterol control improves but cardiovascular disease still increases in Mexico

Despite improved statin use and cholesterol control, cardiovascular disease risk rose in Mexico between 2016 and 2023, according to a study being presented at ACC Latin America 2025 that used region-specific tools to more accurately predict the local disease burden.

18 Sep 2025

Type 2 diabetes accelerates accumulation of chronic diseases across age groups

New research being presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), Vienna (15-19 Sept), reveals type 2 diabetes (T2D) as a critical factor in chronic disease accumulation, particularly during the early stages.

17 Sep 2025

GLP-1RAs linked to lower risk of mortality and cardiovascular events in psoriasis patients

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% lower risk of major cardiovascular events compared to those taking other diabetes or weight-loss medications, new research has shown.

17 Sep 2025

Tai chi improves memory and sleep in older adults with type 2 diabetes

A 12-week randomized trial found that remotely delivered Tai Chi significantly enhanced cognitive performance and sleep quality in older adults with Type 2 Diabetes. These gains surpassed those from supervised fitness walking or usual care, without increasing adverse events.

17 Sep 2025

Projected surge in uninsured will strain local health systems

Jake Margo Jr. stood in the triage room at Starr County Memorial Hospital explaining why a person with persistent fever who could be treated with over-the-counter medication didn't need to be admitted to the emergency room.

17 Sep 2025

New EASD guideline combines clinical standards with lived experience

The guideline was developed in line with internationally recognized standards, including the GRADE methodology and the RIGHT reporting statement, and reflects the EASD's newly established Standard Operating Procedures for guideline development.

17 Sep 2025

A new tool in the fight against obesity: Orforglipron's substantial weight loss results

New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15-19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity that do not have type 2 diabetes.

17 Sep 2025

GLP-1 drugs found to protect against diabetic retinopathy

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published in the journal Pharmaceutics.

17 Sep 2025

The mind-gut connection: How emotional eating affects GLP-1 drug success

GLP-1 receptor agonists like Ozempic can be a lifeline for people with diabetes - helping stabilize blood glucose and lose weight which contributes to diabetes complications. But not everyone benefits equally.

17 Sep 2025

Exercise found to reduce artery hardening after weight loss in adults with obesity

Maintaining weight loss with regular exercise rather than the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide, a drug used to treat type 2 diabetes and obesity, seems to reduce atherosclerosis development in adults with obesity-a leading underlying cause of cardiovascular disease.

17 Sep 2025

Healthy plant-based diet may lower type 2 diabetes risk while reducing greenhouse gas emissions

A diet focused on healthy plant-based foods may lower the risk of type 2 diabetes while reducing greenhouse gas emissions, according to a new study by Solomon Sowah and colleagues from the MRC Epidemiology Unit at the University of Cambridge, United Kingdom, published September 16th in the open-access journal PLOS Medicine.

16 Sep 2025

Cleveland Clinic study shows lasting benefits of weight-loss surgery over GLP-1 medicines

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo weight-loss surgery live longer and face fewer serious health problems compared with those treated with GLP-1 receptor agonist medicines alone.

16 Sep 2025

Younger adults and men with type 2 diabetes face higher risk of sepsis

Living with type 2 diabetes (T2D) may double the risk of developing sepsis-with those aged younger than 60 years and men particularly susceptible, according to a long-term community-based study in Australia, being presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), Vienna (15-19 Sept).

16 Sep 2025

Study warns women with type 2 diabetes against using oral estrogen therapy

In women with type 2 diabetes (T2D), use of hormone replacement therapy (HRT) skin patches is not associated with a higher risk of blood clots or stroke.

15 Sep 2025

High BMI and obesity may not always increase mortality risk

It is possible to be "fat but fit", new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) suggests.

15 Sep 2025

Genetic study shows dual GIPR/GLP1R action curbs binge alcohol use

Researchers used drug-target Mendelian randomization to test whether genetically proxied activation of GLP1R and GIPR influences alcohol-related behaviors. They found that GIPR, especially when combined with GLP1R, was linked to lower binge and heavy drinking, healthier food preferences, improved liver markers, and reduced coronary artery disease risk.

15 Sep 2025

Smoking raises the risk of all subtypes of type 2 diabetes

The characteristics of type 2 diabetes vary from patient to patient and it has been proposed that the condition is made up of four subtypes. Now, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) shows that smoking increases the risk of the condition, regardless of subtype.

13 Sep 2025